CEO Palleiko sold 32,979 shares of KALV at $15.69; holds 369,595 shares post-transaction. Stock up 35.0% in 90 days.
Benjamin L Palleiko, CEO of KalVista Pharmaceuticals, sold 32,979 shares at $15.69 on 2025-07-09, reducing his holdings by 8.2% to 369,595 shares. His cross-ticker track record shows a 100.00% well-timed rate on 1 prior sell, and his prior KALV sale on 2024-02-14 was followed by a 90-day decline of -16.8%. However, the current context differs materially: KALV stock has appreciated 35.0% over the past 90 days and is trading at $15.51, near its 52-week high of $15.99. The company generated $1.6M in quarterly revenue with a negative net income of $-48.5M, reflecting a pre-commercial or early-stage biotech profile with 495.7% annual revenue growth. The timing and magnitude of this sale merit monitoring given the strong recent price momentum and the CEO's historical accuracy on prior trades.